Business Context and Reporting Period
This Form 8-K, dated January 6, 2020, reports the completion of a merger transaction by ArTara Therapeutics, Inc. (formerly Proteon Therapeutics, Inc.) on January 9, 2020. The Company merged with ArTara Subsidiary, Inc. (formerly ArTara Therapeutics, Inc.), resulting in ArTara becoming a wholly-owned subsidiary. The transaction included a 1-for-40 reverse stock split, a name change to ArTara Therapeutics, Inc., and a ticker symbol change from "PRTO" to "TARA" on the Nasdaq Capital Market. The Company is now focused on advancing ArTara's drug development programs.
Key Financial Metrics and Capital Structure
Private Placement: The Company completed a private placement raising an aggregate of approximately $40.5 million. This consisted of:
- 1,896,888 shares of Common Stock sold at approximately $7.01 per share.
- 3,879.356 shares of Series 1 Convertible Non-Voting Preferred Stock sold at $7,011.47 per share.
Capitalization Post-Merger:
- Immediately after the Merger and prior to the Private Placement, former ArTara stockholders owned approximately 75.2% of the fully-diluted common stock, while former Proteon stockholders owned approximately 24.8%.
- Immediately after the Merger, there were 557,631 shares of Common Stock outstanding.
- 18,954 shares of Series A Preferred Stock were converted into 476,276 shares of Common Stock.
Financial Statements: The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. The Company intends to file the required financial statements of ArTara and pro forma financial information as part of an amendment to this report within 71 calendar days.
Material Changes Versus Prior Period
- Corporate Identity: The Company changed its name from Proteon Therapeutics, Inc. to ArTara Therapeutics, Inc.
- Stock Structure: A 1-for-40 reverse stock split was effected. All outstanding Series A Preferred Stock was converted to Common Stock.
- Ownership: A change in control occurred, with former ArTara stockholders becoming the majority owners (approx. 75.2%).
- Liquidity: The Company raised approximately $40.5 million through the private placement, significantly altering its cash position compared to the pre-transaction state.
Guidance, Outlook, Risks, and Unusual Items
Nasdaq Compliance Risk: On January 6, 2020, the Company received notice from Nasdaq regarding a failure to hold an annual meeting of stockholders within 12 months of its fiscal year end. The Company has 45 days to submit a compliance plan and up to 180 days (until June 29, 2020) to regain compliance. Securities will continue to trade while the plan is pending.
Management Commentary: The Company stated its focus is now on advancing ArTara's drug development programs. No specific financial guidance or revenue outlook was provided in this filing.
Unusual Items: The filing details significant executive and board turnover. Former CEO Timothy Noyes and CFO George Eldridge resigned. Jesse Shefferman was appointed President and CEO, and a new board of directors was reconstituted.
Important Facts for Investor Verification
- Pro Forma Financials: Verify the upcoming filing of ArTara's financial statements and pro forma information to assess the combined entity's liquidity and burn rate.
- Nasdaq Compliance: Monitor the submission and acceptance of the Company's plan to regain compliance with Nasdaq listing rules regarding the annual meeting.
- Series 1 Preferred Stock Terms: Review the conversion mechanics of the Series 1 Preferred Stock, which converts at a rate of 1,000 shares of Common Stock per preferred share, subject to a 9.99% beneficial ownership cap.
- Executive Compensation: Note the new employment agreements for CEO Jesse Shefferman (base salary $510,000) and SVP Jacqueline Zummo (base salary $325,000), including severance provisions and equity grants.
- Share Count: Confirm the post-split share count and the impact of the private placement on total outstanding shares and dilution.